Patents by Inventor Yegao Chen

Yegao Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
    Patent number: 9877931
    Abstract: The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs). One embodiment of the present invention also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment of the present invention also has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: January 30, 2018
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Hongjie Zhang, Siu Wai Tsang, Yegao Chen
  • Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
    Publication number: 20170290782
    Abstract: The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs). One embodiment of the present invention also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment of the present invention also has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Hongjie ZHANG, Siu Wai TSANG, Yegao CHEN
  • Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
    Patent number: 9738581
    Abstract: A polyphenol derivative of the stilbenoid family, namely trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, is disclosed as a remedial agent. In particular, the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs) is presented. One embodiment also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 22, 2017
    Assignee: Hong Kong Baptist University
    Inventors: Hongjie Zhang, Siu Wai Tsang, Yegao Chen
  • Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
    Publication number: 20170057896
    Abstract: A polyphenol derivative of the stilbenoid family, namely trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, is disclosed as a remedial agent. In particular, the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs) is presented. One embodiment also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventors: Hongjie ZHANG, Siu Wai TSANG, Yegao CHEN
  • Use of a flavanol glycoside for suppressing activation of stellate cells
    Patent number: 9260466
    Abstract: A method for suppressing activation of pancreatic stellate cells of a subject includes administering a composition comprising a therapeutically effective amount of Eruberin A. A method of preventing, alleviating or treating pancreatic tumors or pancreatic tumors related diseases includes administering a composition comprising a therapeutically effective amount of Eruberin A. The Eruberin A may be extracted from Pronephrium penangianum.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: February 16, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Siu Wai Tsang, Hongjie Zhang, Yegao Chen, Aiping Lu, Albert Sun-Chi Chan, Hongxi Xu, Shilin Chen, Dajian Yang
  • USE OF A FLAVANOL GLYCOSIDE FOR SUPPRESSING ACTIVATION OF STELLATE CELLS
    Publication number: 20140348965
    Abstract: A method for suppressing activation of pancreatic stellate cells of a subject includes administering a composition comprising a therapeutically effective amount of Eruberin A. A method of preventing, alleviating or treating pancreatic tumors or pancreatic tumors related diseases includes administering a composition comprising a therapeutically effective amount of Eruberin A. The Eruberin A may be extracted from Pronephrium penangianum.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Siu Wai Tsang, Hongjie Zhang, Yegao Chen, Aiping Lu, Albert Sun-Chi Chan, Hongxi Xu, Shilin Chen, Dajian Yang